Heidelberg Pharma AG (HPHA.DE)
EUR 2.61
(1.16%)
EUR 2.61
(1.16%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 70.35 Million EUR | -30.05% |
| 2022 | 100.58 Million EUR | 362.83% |
| 2021 | 21.73 Million EUR | 10.83% |
| 2020 | 19.6 Million EUR | -14.71% |
| 2019 | 22.99 Million EUR | -26.29% |
| 2018 | 31.19 Million EUR | -24.82% |
| 2017 | 41.48 Million EUR | 172.22% |
| 2016 | 15.24 Million EUR | 25.94% |
| 2015 | 12.1 Million EUR | -19.48% |
| 2014 | 15.02 Million EUR | -32.64% |
| 2013 | 22.31 Million EUR | -40.85% |
| 2012 | 37.72 Million EUR | 81.22% |
| 2011 | 20.81 Million EUR | 272.29% |
| 2010 | 5.59 Million EUR | -53.46% |
| 2009 | 12.01 Million EUR | -21.63% |
| 2008 | 15.32 Million EUR | -59.27% |
| 2007 | 37.62 Million EUR | -36.98% |
| 2006 | 59.7 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 61.66 Million EUR | -12.35% |
| 2024 Q2 | 71.97 Million EUR | 16.71% |
| 2024 Q3 | 65.77 Million EUR | -8.61% |
| 2023 Q3 | 74.32 Million EUR | -4.66% |
| 2023 Q2 | 77.96 Million EUR | -9.84% |
| 2023 Q1 | 86.47 Million EUR | -14.02% |
| 2023 FY | 70.35 Million EUR | -30.05% |
| 2023 Q4 | 70.35 Million EUR | -5.35% |
| 2022 Q4 | 100.58 Million EUR | 237.47% |
| 2022 Q3 | 29.8 Million EUR | -12.18% |
| 2022 FY | 100.58 Million EUR | 362.83% |
| 2022 Q1 | 20.65 Million EUR | -4.97% |
| 2022 Q2 | 33.93 Million EUR | 64.33% |
| 2021 Q1 | 17.54 Million EUR | -10.54% |
| 2021 Q4 | 21.73 Million EUR | -23.87% |
| 2021 Q2 | 15.69 Million EUR | -10.55% |
| 2021 FY | 21.73 Million EUR | 10.83% |
| 2021 Q3 | 28.54 Million EUR | 81.92% |
| 2020 Q4 | 19.6 Million EUR | -22.8% |
| 2020 Q1 | 19.02 Million EUR | -17.24% |
| 2020 FY | 19.6 Million EUR | -14.71% |
| 2020 Q2 | 29.07 Million EUR | 52.81% |
| 2020 Q3 | 25.39 Million EUR | -12.65% |
| 2019 Q2 | 26.96 Million EUR | -4.79% |
| 2019 FY | 22.99 Million EUR | -26.29% |
| 2019 Q1 | 28.32 Million EUR | -9.19% |
| 2019 Q3 | 25.91 Million EUR | -3.92% |
| 2019 Q4 | 22.99 Million EUR | -11.27% |
| 2018 FY | 31.19 Million EUR | -24.82% |
| 2018 Q4 | 31.19 Million EUR | -10.58% |
| 2018 Q2 | 36.89 Million EUR | -3.06% |
| 2018 Q3 | 34.88 Million EUR | -5.47% |
| 2018 Q1 | 38.06 Million EUR | -8.26% |
| 2017 FY | 41.48 Million EUR | 172.22% |
| 2017 Q4 | 41.48 Million EUR | 174.55% |
| 2017 Q3 | 15.11 Million EUR | -6.65% |
| 2017 Q2 | 16.18 Million EUR | 21.68% |
| 2017 Q1 | 13.3 Million EUR | -12.71% |
| 2016 Q1 | 13.02 Million EUR | 7.66% |
| 2016 FY | 15.24 Million EUR | 25.94% |
| 2016 Q4 | 15.24 Million EUR | 9.36% |
| 2016 Q3 | 13.93 Million EUR | -12.61% |
| 2016 Q2 | 15.94 Million EUR | 22.41% |
| 2015 FY | 12.1 Million EUR | -19.48% |
| 2015 Q1 | 13.99 Million EUR | -6.89% |
| 2015 Q2 | 17.13 Million EUR | 22.48% |
| 2015 Q3 | 15.42 Million EUR | -9.99% |
| 2015 Q4 | 12.1 Million EUR | -21.55% |
| 2014 Q1 | 18.96 Million EUR | -14.98% |
| 2014 Q3 | 16.12 Million EUR | -2.71% |
| 2014 Q2 | 16.57 Million EUR | -12.62% |
| 2014 FY | 15.02 Million EUR | -32.64% |
| 2014 Q4 | 15.02 Million EUR | -6.79% |
| 2013 Q3 | 24.91 Million EUR | -10.96% |
| 2013 Q2 | 27.98 Million EUR | -13.99% |
| 2013 Q1 | 32.53 Million EUR | -13.75% |
| 2013 FY | 22.31 Million EUR | -40.85% |
| 2013 Q4 | 22.31 Million EUR | -10.46% |
| 2012 Q3 | 43.17 Million EUR | 92.62% |
| 2012 FY | 37.72 Million EUR | 81.22% |
| 2012 Q1 | 26.32 Million EUR | 26.48% |
| 2012 Q2 | 22.41 Million EUR | -14.86% |
| 2012 Q4 | 37.72 Million EUR | -12.63% |
| 2011 Q3 | 24.04 Million EUR | -14.5% |
| 2011 Q1 | 8.27 Million EUR | 47.93% |
| 2011 FY | 20.81 Million EUR | 272.29% |
| 2011 Q4 | 20.81 Million EUR | -13.44% |
| 2011 Q2 | 28.12 Million EUR | 240.07% |
| 2010 Q1 | 14 Million EUR | 16.55% |
| 2010 FY | 5.59 Million EUR | -53.46% |
| 2010 Q4 | 5.59 Million EUR | -49.15% |
| 2010 Q3 | 10.99 Million EUR | 62.96% |
| 2010 Q2 | 6.74 Million EUR | -51.81% |
| 2009 FY | 12.01 Million EUR | -21.63% |
| 2009 Q4 | 12.01 Million EUR | 0.0% |
| 2008 FY | 15.32 Million EUR | -59.27% |
| 2007 FY | 37.62 Million EUR | -36.98% |
| 2006 FY | 59.7 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioNTech SE | 23 Billion EUR | 99.694% |
| CureVac N.V. | 788.89 Million EUR | 91.082% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 95.129% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 95.129% |
| BRAIN Biotech AG | 70.93 Million EUR | 0.823% |
| Formycon AG | 890.36 Million EUR | 92.098% |
| Medigene AG | 31.71 Million EUR | -121.822% |